Caprolactam Chemicals Limited Fundamental Analysis (BSE: CAPRO.BO)
Caprolactam Chemicals Limited Fundamental Analysis (BSE: CAPRO.BO)
Caprolactam Chemicals Limited (BSE: CAPRO.BO) shows weak financial fundamentals with a PE ratio of 53.82, profit margin of 4.85%, and ROE of 6.55%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 38.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CAPRO.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakCAPRO.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateCAPRO.BO shows balanced valuation metrics.
Growth Score
ModerateCAPRO.BO shows steady but slowing expansion.
Financial Health Score
ModerateCAPRO.BO shows balanced financial health with some risks.
Profitability Score
WeakCAPRO.BO struggles to sustain strong margins.
Key Financial Metrics
Is CAPRO.BO Expensive or Cheap?
P/E Ratio
CAPRO.BO trades at 53.82 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CAPRO.BO's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Caprolactam Chemicals Limited at 3.35 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 7.24 times EBITDA. This is generally considered low.
How Well Does CAPRO.BO Make Money?
Net Profit Margin
For every $100 in sales, Caprolactam Chemicals Limited keeps $4.85 as profit after all expenses.
Operating Margin
Core operations generate 27.31 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.55 in profit for every $100 of shareholder equity.
ROA
Caprolactam Chemicals Limited generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Caprolactam Chemicals Limited produces operating cash flow of $10.20M, showing steady but balanced cash generation.
Free Cash Flow
Caprolactam Chemicals Limited generates weak or negative free cash flow of $1.57M, restricting financial flexibility.
FCF Per Share
Each share generates $0.34 in free cash annually.
FCF Yield
CAPRO.BO converts 0.71% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
53.82
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.003
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.35
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.60
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How CAPRO.BO Stacks Against Its Sector Peers
| Metric | CAPRO.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 53.82 | 27.23 | Worse (Expensive) |
| ROE | 6.55% | 1227.00% | Weak |
| Net Margin | 4.85% | 443.00% | Weak |
| Debt/Equity | 0.00 | 0.73 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 3.12 | Weak Liquidity |
| ROA | 0.00% | 2724.00% | Weak |
CAPRO.BO outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Caprolactam Chemicals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Commodity, Value
EPS CAGR
N/A
Industry Style: Cyclical, Commodity, Value
FCF CAGR
N/A
Industry Style: Cyclical, Commodity, Value